A Phase II Study of HLX22 in Combination With Trastuzumab Deruxtecan in HER2-low, Hormone Receptor Positive Locally Advanced or Metastatic Breast Cancer Patients

PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

April 16, 2025

Primary Completion Date

June 1, 2027

Study Completion Date

December 1, 2029

Conditions

HER2-low Hormone Receptor Positive Breast Cancer

Interventions

DRUG

HLX22

HLX22 15mg/kg Q3W

DRUG

Trastuzumab Deruxtecan

Trastuzumab Deruxtecan 5.4mg/kg Q3W

Trial Locations (1)

RECRUITING

Fudan University Shanghai Cancer Center, Shanghai

All Listed Sponsors

lead

Shanghai Henlius Biotech

INDUSTRY